Seroprevalence and protective effect of SARS-CoV-2 immunity against symptomatic SARS-CoV-2 infection among children and adolescents in Nakhon Phanom province, Thailand 2024 – 2025

Authors

  • Sutthichai Nakphook Nakhon Phanom Hospital ,Kasetsart University Chalermphrakiat Sakonnakhon Province Campus
  • Kriengkrai Prasert Nakhon Phanom Hospital , Kasetsart University Chalermphrakiat Sakonnakhon Province Campus
  • Rathanith Jaratworapatra Nakhon Phanom Hospital
  • Prabda Praphasiri Nakhon Phanom Hospital , Kasetsart University Chalermphrakiat Sakonnakhon Province Campus

Keywords:

Seroprevalence, SARs-CoV-2 immunity, Protective effect, Children and adolescents

Abstract

Background :  The Omicron variants have altered the epidemiology of COVID-19, particularly among children and adolescent , who commonly experience mild or asymptomatic infection but may still contribute to community transmission. Understanding population-level immunity in this age group is important for guiding public health strategies.This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies and to to assess the association between baseline seropositivity and the risk of symptomatic SARS-CoV-2 infection  among children and adolescents in Nakhon Phanom province, Thailand. Methods : A population-based prospective cohort study was conducted aming children and adolescents aged 6 months to 17 years using stratified random sampling by age group. A total  of 999  participants were enrolled.  Blood samples were collected at enrollement, 6 months, and 12 months to measure anti-S and anti-N SARS-CoV-2 IgG antibodies using ELISA.. Participants were followed weekly for COVID-19–like illness, and symptomatic infections were confirmed by multiplex reverse transcription polymerase chain reaction (multiplex RT-PCR). Cox proportional hazards regression was used to evaluate the association between baseline anti-S IgG seropositivity and the risk of symptomatic SARS-CoV-2 infection, adjusting for relevant confounders. Results :  The mean age of participants was 8.1 years and 53.3% had received at least one dose of COVID-19 vaccine. Anti-S IgG seropositivity exceeded 80% in all age throughout the 12-month follow-up. During follow-up, 439 episodes of COVID-like illness were reported, of which 32 were confirmed SARS-CoV-2 infections. Baseline anti-S IgG seropositivity was associated with a lower risk of symptomatic SARS-CoV-2 infection (Hazard Ratio: 0.64; 95% confidence interval 0.23–1.81), corresponding to a protective effect of 36%, although the association was notstatistical significance. Conclusions  :   Children and adolescents in Nakhon Phanom province exhibited a high seroprevalence of SARS-CoV-2 antibodies throughout the study period. Baseline seropositivity showed a non-significant trend toward reduced risk ofsymptomatic SARS-CoV-2 infection. These findings highlight the importance ofcontinued surveillance and targeted vaccination strategies focusing on high-risk pediatric and adolescentspopulations.

References

Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboot W, et al. Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020. Vol. 25, Eurosurveillance. 2020.

Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020–2022. Arch Virol. 2023;168(1).

Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S, Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. Adv Prev Med. 2021;2021.

Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Vol. 7, Signal Transduction and Targeted Therapy. 2022.

Romanchuk LI, Koloskova OK. PECULIARITIES OF THE CORONAVIRUS INFECTION CLINICAL COURSE CAUSED BY SARS-COV2 IN CHILDREN POPULATION (LITERARY REVIEW). Clin Exp Pathol. 2024;22(4).

Coffin SE, Rubin D. Yes, Children Can Transmit COVID, but We Need Not Fear. Vol. 175, JAMA Pediatrics. 2021.

Paul LA, Daneman N, Schwartz KL, Science M, Brown KA, Whelan M, et al. Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. JAMA Pediatr. 2021;175(11).

สำนักสื่อสารความเสี่ยงและพฤติกรรม. https://ddc.moph.go.th/brc/news.php?news=40060&deptcode=brc. 2024. ผลกระทบของวัคซีนโควิด 19 และข้อมูลการเฝ้าระวังเหตุการณ์ไม่พึงประสงค์ที่เกิดภายหลังการได้รับวัคซีน.

สมาคมโรคติดเชื้อเด็กแห่งประเทศไทย. https://www.pidst.net/A1524.html. 2568. คําแนะนําการฉีดวัคซีนป้องกันโรคโควิด-19 สําหรับเด็กและวัยรุ่น ฉบับที่ 13.

Lorenz E, Souares A, Amuasi J, Loag W, Deschermeier C, Fusco D, et al. Seroprevalence of SARS-CoV-2 in urban settings in three sub-Saharan African countries (SeroCoV): A study protocol for a household-based cross-sectional prevalence study using two-stage cluster sampling. BMJ Open. 2021;11(12).

Clarke KEN, Kim Y, Jones J, Lee A, Deng Y, Nycz E, et al. Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care—September 2021 to February 2022. Journal of Infectious Diseases. 2023;227(3).

World Health Organization. https://www.who.int/westernpacific/emergencies/covid-19/information/asymptomatic-covid-19. 2023. COVID-19: symptoms.

QIAGEN. https://www.qiagen.com/ca/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-ca. 2025. QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Barouch DH. Covid-19 Vaccines — Immunity, Variants, Boosters. New England Journal of Medicine. 2022;387(11).

Movsisyan M, Chopikyan A, Kasparova I, Hakobjanyan G, Carrat F, Sukiasyan M, et al. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients. Sci Rep. 2022;12(1).

Abdullahi A, Frimpong J, Cheng MTK, Aliyu SH, Smith C, Abimiku A, et al. Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population. American Journal of Tropical Medicine and Hygiene. 2023;109(4).

Suntronwong N, Vichaiwattana P, Klinfueng S, Puenpa J, Kanokudom S, Assawakosri S, et al. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study. PLoS One. 2023;18(4 April).

Department of Medical Sciences Ministry of Public Health. https://www.dmsc.moph.go.th/th/detailAll/2997/nw/25. 2568. กรมวิทย์ฯ เฝ้าระวังสายพันธุ์โควิด 19 พบโอมิครอนสายพันธุ์ JN.1 ยังเป็นสายพันธุ์หลักในไทย.

Hart JD, Ong DS, Chokephaibulkit K, Ong-Lim AT, Vereti I, Crawford NW, et al. Considerations for vaccinating children against COVID-19. Vol. 7, BMJ Paediatrics Open. 2023.

Chantasrisawad N, Puthanakit T, Tangsathapornpong A, Techasaensiri C, Phongsamart W, Suwanpakdee D, et al. Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines (Basel). 2022;10(6).

Suryawanshi YN, Biswas DA. Herd Immunity to Fight Against COVID-19: A Narrative Review. Cureus. 2023.

Downloads

Published

2026-01-19

How to Cite

1.
Nakphook S, Prasert K, Jaratworapatra R, Praphasiri P. Seroprevalence and protective effect of SARS-CoV-2 immunity against symptomatic SARS-CoV-2 infection among children and adolescents in Nakhon Phanom province, Thailand 2024 – 2025. Nakhonphanom Hosp J [internet]. 2026 Jan. 19 [cited 2026 Feb. 6];12(3):E285458. available from: https://he01.tci-thaijo.org/index.php/nkpjournal_9/article/view/285458